类风湿性关节炎是对阿尔茨海默病的保护因素:双向的双样本孟德尔随机化研究
Guo-Shuai Li1, Yong-Ze Yang2,3, Guo-Rong Ma2,3
1Gansu Wuwei Hospital of Traditional Chinese Medicine, Wuwei, China.
Inflammopharmacology
|December 27, 2023
概括
这项研究发现,对类风湿性关节炎 (RA) 的遗传敏感性可能会降低患阿尔茨海默病 (AD) 的风险. 然而,对阿尔茨海默氏症的遗传敏感性似乎不会对RA风险产生因果影响.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 流行病学研究表明,类风湿性关节炎 (RA) 和阿尔茨海默氏病 (AD) 之间存在联系.
- 确切的RA和AD之间的因果关系仍有待阐明.
- 这项研究调查了RA和AD之间潜在的双向因果关系.
研究的目的:
- 确定对类风湿性关节炎 (RA) 的遗传易感性是否会因果影响阿尔茨海默病 (AD) 的风险.
- 调查是否对阿尔茨海默病 (AD) 的遗传易感性因果关系影响类风湿性关节炎 (RA) 的风险.
主要方法:
- 利用公开可用的全基因组关联研究 (GWAS) 数据集.
- 采用双向的双样本孟德尔随机化 (TSMR) 分析.
- 应用了多种统计方法,包括反变量加权 (IVW) 和加权中位数方法.
主要成果:
- 对RA的遗传易感性显示出与AD风险降低的显著因果关系 (OR=0.959,P=2.752E-05).
- 在AD的遗传易感性和RA风险之间没有发现显著的因果关系 (IVW,P=0.576).
结论:
- 风湿性关节炎的遗传易感性与阿尔茨海默病的风险降低有关.
- 阿尔茨海默病的遗传易感性似乎对类风湿性关节炎的风险没有因果关系.
相关概念视频
Alzheimer's Disease: Overview
491
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
491
Psychoneuroimmunology: Diabetes and Cancer
29
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
29
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


